Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype
GSK plc announced that the China National Medical Products Administration has approved Nucala (mepolizumab), as an add-on maintenance treatment for severe eosinophilic asthma in adults…
Read More...
Read More...